Clinical trial · Observational
RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)
Real World Effectiveness of Capmatinib in Patients With Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
CapmATU study will evaluate time to treatment failure, progression-free survival, overall survival, best response and safety in patients with advanced MET-dysregulated non-small cell lung cancer who received capmatinib as part of an expanded access program. Those outcomes will be correlated to clinical, pathological, and radiological characteristics of patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| MET Alterations | — | UNRESOLVED | — |
| METex14 Mutations | — | UNRESOLVED | — |
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Capmatinib | Drug | Capmatinib | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- time to treatment failure
- timeFrame
- 2 years
- description
- time to treatment failure in patients with advanced NSCLC harboring a METex14 mutation receiving capmatinib as part of the French compassionate use program (ATU)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically or cytologically confirmed locally advanced or metastatic NSCLC (Stage IIIB or IV accordingly to American Joint Committee on Cancer \[AJCC\] classification) at time of capmatinib initiation * Presence of a MET dysregulation diagnosed on tumor sample and/or on liquid biopsy * Patients who were informed about the study and accepted for their data to be collected. * Patients who received at least one dose of treatment with capmatinib as part of the compassionate use program (ATU), whatever the line of treatment. * Selection period spans from June 1st 2019 (date of start of French ATU) until August 31st 2021 for first dose of capmatinib. * Age \>18 y Exclusion Criteria: * Patients enrolled in a clinical trial assessing treatment with capmatinib. (ATU was granted to patients unable to meet eligibility criteria for on-going recruiting trials, unable to participate to other clinical trials, or because other medical interventions were not considered appropriate or acceptable). * Patients who were included in the French Early Access Program (ATU program) but did not receive any capmatinib treatment. * Patients who have expressed explicit refusal to collect his or her data * Patients with a psychiatric history that hinders the comprehension of the information leaflet * Patients under curatorship or guardianship * Unability to obtain data collection
References
Publications (0)
Data not yet available